Introduction {#s1}
============

Human parainfluenza virus type 1 (HPIV-1) causes upper and lower respiratory infections (URI, LRI) in infants, young children, and the elderly. The virus also causes more severe disease in immunocompromised patients and those with chronic medical conditions [@pone.0046048-Counihan1]--[@pone.0046048-Henrickson1]. Children under 5 years old and particularly those children younger than 1 year are the most commonly hospitalized by HPIV-1 infection [@pone.0046048-Iwane1]. In the United States, the rate of HPIV-1-associated hospitalization among children younger than 5 years is estimated at 0.32--1.6 per 1000 children [@pone.0046048-Counihan1]. Estimates of annual hospitalizations in the U.S. due to HPIV-1 vary from 5,800 to 28,900 [@pone.0046048-Counihan1], [@pone.0046048-Henrickson2].

HPIV-1 is one of four distinct HPIV serotypes all of which are enveloped, negative--sense, ssRNA viruses belonging to the *Paramyxoviridae* family. The function and structure of the viral genes has been explored using mutant HPIV-1 viruses generated with a reverse genetics system [@pone.0046048-McAuliffe1], [@pone.0046048-Newman1] or cell culture [@pone.0046048-Bousse1]--[@pone.0046048-Thompson1]. Evolutionary studies of HPIV-1 were performed in the 1990s using the hemagglutinin-neuraminidase (HN) and fusion (F) genes [@pone.0046048-Ambrose1]--[@pone.0046048-Hetherington1]. However, these studies are now dated and no evolutionary studies based on the complete genome of HPIV-1 have ever been conducted. Not only is there very little evolutionary data on HPIV-1whole genomes, but the publicly available sequence data for HPIV-1 is also extremely limited. To date there is only one complete genome sequence and 329 partial sequences. Many of these sequences are from mutant viruses created for the development of vaccines and therapeutic agents and therefore not useful for evolutionary analyses. Of the wild-type HPIV-1 sequences, most are partial sequences of the HN gene. Limited genomic data and poorly understood/studied HPIV-1 evolution has also been an impediment to the development of molecular diagnostics for HPIV-1. To address these gaps in knowledge and data, we developed a whole genome sequencing protocol for HPIV-1 from clinical samples and low passage virus isolates and report the genome sequences for 40 HPIV-1 strains. Thirty-nine of these strains were collected in Milwaukee, Wisconsin during 1997--1999, 2005--2007 and 2009--2010 and one was obtained from the American Type Culture Collection. Using these new data, we characterized the evolutionary pattern of HPIV-1 over the past 14 years in Milwaukee, WI and combined our data with previously published HN gene sequences from viruses collected from the USA and Japan over a 44-year period (1966--2010) to further examine the evolutionary pattern of HPIV-1.

Materials and Methods {#s2}
=====================

Ethics Statement {#s2a}
----------------

All clinical samples were collected under protocols allowing sequencing approved by the Medical College of Wisconsin and Children\'s Hospital of Wisconsin institutional review boards. Some samples were approved to be collected retrospectively, de-identified, and did not require consent. The remaining samples were collected with written informed consent (from parent/guardian).

Clinical Specimen and Isolates {#s2b}
------------------------------

Nasal swab specimens were collected from Children\'s Hospital of Wisconsin and its affiliated clinics. After collection, nasal swabs from each patient were immediately put into 3 mL of M4 viral transport medium (Remel, Lenexa, KS) and kept at 2--8°C. On the day of collection, 500 µL aliquots of each specimen were prepared and one aliquot from each specimen was tested in a one-step real-time RT-PCR assay for HPIV-1, -2, -3, -4 and human metapneumovirus (HMPV) that was developed in the clinical laboratory of the Midwest Respiratory Virus Program (MRVP). The remaining aliquots of each clinical specimen were frozen at −80°C for later use. Twenty-six HPIV-1 positive clinical specimens were collected during the 2009--2010 HPIV-1 season and used for this sequencing project. An additional 10 specimens collected during 1997--1999, one specimen collected in 2005, and two specimens collected in 2007 (using the same standard collection method), were retrieved from the MRVP virus bank. These 13 specimens tested positive for HPIV-1, at the time of collection, using the Hexaplex, a multiplex RT-PCR enzyme hybridization assay [@pone.0046048-Fan1]. The C-35 strain, isolated in Washington D.C. in 1957, was obtained from American Type Culture Collection (ATCC, Rockville, MD). This strain was passaged 20 times at ATCC and one time in our lab. The passage history before the strain was sent to ATCC is not clear.

Because clinical specimens are a limited resource, all specimens, except for the 2005 and 2007 samples were inoculated onto Rhesus monkey kidney cells (LLC-MK2, ATCC, Rockville, MD) to propagate the viruses for future experiments. In brief, LLC-MK2 cells were cultured in 6-well plates at 37°C and 5% CO~2~ with Eagle\'s minimal essential medium (EMEM, Lonza, Walkersville, MD) containing 10% fetal bovine serum (HyClone, Logan, UT) and 1% Penicillin/Streptomycin (pen/strep) (Gibco, Grand Island, NY) until 90% confluence was achieved. Cells were washed twice with EMEM and then 100 µL of clinical specimen was combined with 100 µL of EMEM and added to each well. The plates were incubated at 37°C for 1 hour and gently rocked every 15 minutes to avoid drying of cells. Following incubation, 3 mLs of virus growth media \[EMEM containing: 0.09% bovine serum albumin (BSA) (MP Biomedicals, Solon, OH), 2.4 µg/mL trypsin (Worthington, Lakewood, NJ), 1% pen/strep (Gibco) and 1% fungizone (Gibco)\], was added into each well and the cells were returned to the incubator. Fifty µL of culture supernatant was used for a hemagglutination assay with guinea pig red blood cells (Colorado Serum Company, Denver, CO) on days 2, 4, 6, 8 and 10 post-inoculation. HPIV-1 viruses were harvested when the hemagglutination assay was positive. The supernatant from hemagglutination negative cultures was harvested at day 10 and blind passaged to new 6-well plates LLC-MK2 cells.

Of the 39 HPIV-1 viruses collected in Milwaukee, 10 were sequenced directly from clinical nasal swab specimens, 16 from low-passage (1--2 passages) clinical isolates and 14 were sequenced initially using clinical specimens, but gaps were filled in using low-passage isolates obtained from that specimen. [Table 1](#pone-0046048-t001){ref-type="table"} shows the pertinent information for each HPIV-1 strain including: sample type, the amount of sequence data available, and GenBank Accession number.

10.1371/journal.pone.0046048.t001

###### Strain Information for all 40 HPIV-1 Genomes Sequenced.

![](pone.0046048.t001){#pone-0046048-t001-1}

  GenBank Accession                           Strain name                           Collection date   Start to end of genomes   Sample type[\#](#nt102){ref-type="table-fn"}                                              
  ------------------- ------------------------------------------------------------ ----------------- ------------------------- ---------------------------------------------- ------------------------------------------- ---------
  JQ901971                            HPIV-1/c35/1957 (ATCC VR-94)                       1957                   n/a                                 n/a                                        29-15550                       I
  JQ901975                               HPIV-1/WI/629-001/1997                          1997                   10                                   3                                         29-15567                    I and S
  JQ901972                               HPIV-1/WI/629-002/1997                          1997                    9                                   22                                        29-15539                       I
  JQ901976                               HPIV-1/WI/629-003/1997                          1997                   10                                   16                                        76-15567                       I
  JQ901973                               HPIV-1/WI/629-004/1997                          1997                    9                                   24                                        77-15560                       I
  JQ901974              HPIV-1/WI/629-005/1997[\*](#nt101){ref-type="table-fn"}          1997                    9                                   25                        78-15555[a](#nt103){ref-type="table-fn"}       I
  JQ901977                               HPIV-1/WI/629-006/1997                          1997                   11                                   4                                         77-15560                       I
  JQ901979                               HPIV-1/WI/629-007/1997                          1997                   11                                   22                                        28-15558                       I
  JQ901978                               HPIV-1/WI/629-008/1997                          1997                   11                                   22                                        28-15568                       I
  JQ901980                               HPIV-1/WI/629-009/1997                          1997                   12                                   3                                         29-15565                       I
  JQ901981                               HPIV-1/WI/629-010/1999                          1999                    3                                   5                                         29-15549                       I
  JQ901982                               HPIV-1/WI/629-A31/2005                          2005                   11                                   9                                         28-15555                       S
  JQ901983                               HPIV-1/WI/629-003/2007                          2007                   n/a                                 n/a                                        29-15552                       I
  JQ901984                               HPIV-1/WI/629-030/2007                          2007                   n/a                                 n/a                                        28-15534                       I
  JQ901985                               HPIV-1/WI/629-001/2009                          2009                   n/a                                 n/a                                        27-15548                       I
  JQ901991                             HPIV-1/WI/629-D01150/2009                         2009                   10                                   6                                         29-15568                       S
  JQ901987             HPIV-1/WI/629-D00057/2009[\*](#nt101){ref-type="table-fn"}        2009                    9                                   29                        78-15485[b](#nt104){ref-type="table-fn"}       S
  JQ901998                             HPIV-1/WI/629-D00387/2009                         2009                   10                                   22                                        78-15557                    I and S
  JQ901989                             HPIV-1/WI/629-D00712/2009                         2009                   10                                   2                                         29-15567                       S
  JQ902003                             HPIV-1/WI/629-D01145/2009                         2009                   11                                   23                                        100-15548                   I and S
  JQ901996                             HPIV-1/WI/629-D01164/2009                         2009                   10                                   20                                        100-15446                   I and S
  JQ901992                             HPIV-1/WI/629-D01202/2009                         2009                   10                                   6                                         29-15568                       S
  JQ902006             HPIV-1/WI/629-D01250/2009[\*](#nt101){ref-type="table-fn"}        2009                   12                                   4                         100-15539[C](#nt105){ref-type="table-fn"}   I and S
  JQ902000                             HPIV-1/WI/629-D01463/2009                         2009                   11                                   7                                         100-15481                   I and S
  JQ902004                             HPIV-1/WI/629-D01575/2009                         2009                   11                                   30                                        100-15549                   I and S
  JQ901988                             HPIV-1/WI/629-D01662/2009                         2009                    9                                   29                                        29-15539                       S
  JQ901986                             HPIV-1/WI/629-D01681/2009                         2009                    9                                   29                                        27-15557                       I
  JQ902008             HPIV-1/WI/629-D01774/2009[\*](#nt101){ref-type="table-fn"}        2009                   10                                   3                         81-15539[d](#nt106){ref-type="table-fn"}       I
  JQ902001                             HPIV-1/WI/629-D01790/2009                         2009                   11                                   7                                         100-15482                   I and S
  JQ901995                             HPIV-1/WI/629-D01809/2009                         2009                   10                                   11                                        28-15539                       I
  JQ902007                             HPIV-1/WI/629-D02039/2009                         2009                   12                                   10                                        100-15548                   I and S
  JQ902002                             HPIV-1/WI/629-D02072/2009                         2009                   11                                   18                                        100-15544                   I and S
  JQ901993                             HPIV-1/WI/629-D02130/2009                         2009                   10                                   6                                         29-15568                       S
  JQ901999                             HPIV-1/WI/629-D02143/2009                         2009                   10                                   24                                        100-15492                   I and S
  JQ901990                             HPIV-1/WI/629-D02161/2009                         2009                   10                                   3                                         29-15550                       S
  JQ902005                             HPIV-1/WI/629-D02209/2009                         2009                   11                                   30                                        100-15488                   I and S
  JQ901994                             HPIV-1/WI/629-D02401/2009                         2009                   10                                   6                                         29-15568                       S
  JQ901997                             HPIV-1/WI/629-D01900/2009                         2009                   10                                   21                                        100-15492                   I and S
  JQ902010                             HPIV-1/WI/629-D02071/2010                         2010                    3                                   2                                         100-15488                      S
  JQ902009             HPIV-1/WI/629-D02211/2010[\*](#nt101){ref-type="table-fn"}        2010                    2                                   15                        100-15156[e](#nt107){ref-type="table-fn"}   I and S

These sequences still have some gaps. Gene sequences with gaps in the coding region were not used for the coding region (ORF) analysis for that specific gene.

The sample type indicates whether the genome was sequenced from a clinical isolate (I), a clinical specimen (S) or a combination of the two (I and S).

Sequence of HPIV-1/WI/629-005/1997 has gaps at nts 8270--9308, 9520--10136, 10172--10175, 10640--10701, 11474--11883, 12475--12507 and 13196--13590.

Sequence of HPIV-1/WI/629-D00057/2009 has gaps at nts 2199--2262, 8172--8653, 9750--10223, and 11823--11926.

Sequence of HPIV-1/WI/629-D01250/2009 has gaps at nts 8271--8802.

Sequence of HPIV-1/WI/629-D01774/2009 has gaps at nts 2301--2326, 3671--3772, 4070--4253, and 11906--13627.

Sequence of HPIV-1/WI/629-D02211/2010 has gaps at nts 2995--3041, 3676--3740, 6408--7517, and 15157--15445.

Primers for Amplification and Sequencing {#s2c}
----------------------------------------

The HPIV-1 genome was amplified by RT-PCR as ten overlapping fragments. Amplification primers were designed using an on-line primer design tool \[IDT PrimerQuest ([www.IDTDNA.com](http://www.IDTDNA.com), Integrated DNA Technologies, Inc., Coralville, IA)\] based on sequences retrieved from GenBank (primarily based on Accession \# AF457102). Amplification primers were designed to, have melting temperatures of 55--60°C, have GC contents of around 50%, and amplify about 2 Kb of the HPIV-1 genome. The amplification primers were designed to cover only nucleotides (nt) 1--15575 of the 15600 nt genome as the low GC content at the extreme 5′ terminus makes primer design and amplification difficult.

The first and second fragments amplify similar regions of the genome and use the same reverse primer. The first fragment uses a forward primer that binds to the first nt of the genome; however this primer has a low GC content (37%) and only worked for 50% of the strains. The forward primer of the second fragment binds to the genome starting at nt 77. Strains that failed to produce an RT-PCR product for the first fragment were sequenced beginning slightly downstream of the 3′ terminus at the start of the second fragment.

The RT-PCR amplified fragments were sequenced with 44 primers. The amplification primers were also used as sequencing primers. All primers were synthesized by Integrated DNA Technologies (IDT) and are listed in [Table 2](#pone-0046048-t002){ref-type="table"}. Those primers shown in bold print were used for both amplification and sequencing while those shown in plain print were used only for sequencing.

10.1371/journal.pone.0046048.t002

###### HPIV-1 Primer Information for Amplification and Sequencing.

![](pone.0046048.t002){#pone-0046048-t002-2}

  Name               Sequence[\*](#nt108){ref-type="table-fn"}   \% GC    Tm    Fragment
  ----------------- ------------------------------------------- ------- ------ ----------
  **P1F1−27**             **ACCAAACAAGAGGAAAAACTTGTTTGG**         37     56.8      1
  **P1F77−23**              **AGGGACAAGTCACAGACATTTGA**          43.5    55.9      2
  **P1R509+24**            **CATAGGTCCAAACAACCACTCTGT**          45.8    56.6    1 & 2
  **P1F234−24**            **ACATTAGGCCCGAGTGTGACAGAT**           50      60       3
  **P1R2336+24**           **TCCCTCAACTTGGTCTTCTTCCCT**           50     59.3      3
  **P1F2208−24**           **ACCCTCTACCTGAGAATATGGGCA**           50     58.8      4
  **P1R4352+24**           **CCTAGGTGTACCATGAAGTTGAGC**           50     56.9      4
  **P1F4133−24**           **ACCTCAATGTCTCCCAGTCGACAA**           50     59.6      5
  **P1R6538+24**           **TGTGCCATCCTCCAACTGCTGATA**           50      60       5
  **P1F6277−24**           **GCGGGACAAACAGAATACCAGTGA**           50     58.9      6
  **P1R8308+24**           **CACCTGATATGCATTCTCTCGGAC**           50     56.9      6
  **P1F8123−23**            **CTTAGGTGCCGAAGGGAGGCTAC**          56.5    58.9      7
  **P1R10202+24**          **TCCCATGCTGCTTTCCTAGGTGAT**           50     59.9      7
  **P1F10061−24**          **GAATGCACAAGGATCCAACTCTGC**           50     58.2      8
  **P1R11995+24**          **TCGTTGTATCAAGCATCCCGGCTA**           50     59.9      8
  **P1F11751−24**          **TGGGCATCAGACCCTTATTCATGC**           50      59       9
  **P1R13842+24**          **AGGATCCCAGTCCTCTAAGACTTC**           50     56.9      9
  **P1F13501−24**          **TCTTTATGCGTGATTGGCAAGAGG**          45.8    57.6      10
  **P1R15575+25**          **CCAGACAAGAGTTTAAGAAATATCG**          36     51.5      10
  P1R278+24                  GAGTGGGCTAAGAAAGTGGTTGCT             50      59   
  P1F710−24                  AGCATTCAGACAGGATGGAACCGT             50     60.1  
  P1R1865+24                 TTCGGCTTCAGGATCCCTCTCAAA             50     59.7  
  P1F2783−24                 ACCGCAAATGAAGAGGAAACCAGC             50     59.8  
  P1R3764+27                CCTACCTTGACTATTCTGATGTGAGGG          48.1    57.8  
  P1F4630−24                 CTGTGTTCCAACCTGCAATTCCGA             50     59.6  
  P1R5775+24                 GAGAGATGATAATGCCTGCAAGGT            45.8    56.6  
  P1F4455−24                 TCTCTCGGGCTTGTAGGTGGAATA             50     58.8  
  P1R6065+24                 ACAGTTTGTGACATCTGCACCTCC             50     59.1  
  P1F6803−24                 TCCACAACTTCACCAATCAGGTGT            45.8    58.6  
  P1F7677−23                  TCTGTAATAGCTGCAGGAACAA             40.9    53.9  
  P1R7856+26                CCACTTCCTACACTTGGATACATTGC            50     58.7  
  P1F8740−21                   ACTTAGGGTTAATGCCTGCCT             47.6    55.9  
  P1F8513−24                 TCATTTCGGGAAGGGCTACTGCTT             50     60.2  
  P1R8819+23                  TCGGAGAGTTCAAGTGACATTCT            43.5    55.7  
  P1F9519−23                  TCTTCAGCTGGACGACTCGATAA            47.8    57.2  
  P1R9760+23                  TGCTGTCTGCTTCTGAATCTGTG            47.8     57   
  P1R9667+22                  AGTTACAGGGTCATCCAACTGT             45.5    55.5  
  P1F10576−24                CAGGTGTTCCAAGATCCAACTCAG             50     57.3  
  P1R10701+23                 TCGGTTGATGAGTCTGCAGCTTT            47.8    58.6  
  P1R11565+24                ACCCTCCTATGTTAGCTGGGATCA             50     58.8  
  P1F12388−24                GAAGTCCTGCCATACGTATCCCTT             50      58   
  P1R13287+24                CCCATATTTCATCCCTCCCTCTGA             50     57.6  
  P1F14090−25                CGGGATTAATAGCACCAGTTGTTTG            44     56.1  
  P1R15017+23                 ATCCGAGTCCACTCAAAGATTGT            43.5    55.8  

Bold font represents oligonucleotides used for amplification. All primers were used for sequencing. The primer names are designed as follows: 1) The "P1" at the beginning indicates that these are HPIV-1 primers, 2) The "F" or "R" located at the third position of the primer name indicates whether the primer is in the forward or reverse orientation, 3) the number between the "F" or "R" and the hyphen corresponds to the nucleotide position of the 5′ end of the oligonucleotide in the HPIV-1 genome, and 4) adding or subtracting the number at the end of the primer name from the nucleotide position of the 5′ end of the oligonucleotide is the nucleotide position of the 3′ end of the oligonucleotide.

Nucleotide Extraction, Amplification, Purification and Electrophoresis {#s2d}
----------------------------------------------------------------------

Viral RNA was extracted from 400 µL of clinical specimen or tissue culture supernatant using the NucliSENS easyMAG (bioMérieux, Durham, NC) according to the manufacturer\'s protocol and eluted in 50 µL of elution buffer.

cDNA was synthesized in a 20 µL reaction mixture containing 2.5 mM random hexamers (Applied Biosystems, Carlsbad, CA), 4 mM dNTPs (Applied Biosystems), 4 mM MgCl~2~ (Applied Biosystems,), 1 U/µL RNase inhibitor (Applied Biosystems), 2.5 U/µL MuLv reverse transcriptase (Applied Biosystems) and 3 µL RNA. The reaction mixture was incubated for 5 minutes at 25°C and then for 14 minutes at 42°C followed by 1 minute at 95°C. Ten µL of cDNA was amplified by adding 40 µL of PCR mix containing a pair of PCR primers, 2.25 mM MgCl~2~, 2.5 U of Faststart hot start polymerase (Applied Biosystems) and the appropriate buffers to support PCR. The final concentration of each primer was 200 nM. Amplification was performed with a touch-down PCR program. After an initial denaturing at 94°C for 5 minutes, the PCR was done for 5 touch-down cycles with denaturing at 95°C for 45 seconds, annealing at 66°C for 5 minutes, and extension at 72°C for 90 seconds. The annealing temperature was decreased by 2°C after each cycle. This was followed by another 2 touch-down cycles with denaturing at 95°C for 45 seconds, annealing at 56°C for 2 minutes, and extension at 72°C for 90 seconds. Again, the annealing temperature was decreased by 2°C after each cycle. Finally, 30 standard PCR cycles were performed with denaturing at 95°C for 45 seconds, annealing at 52°C for 2 minutes and extension at 72°C for 90 seconds. The PCR was finished with a final extension at 72°C for 10 minutes.

The PCR products were purified with a Millipore MultiScreen PCR~μ96~ filter plate (Millipore, Billerica, MA) on the Biomek FX workstation (Beckman Coulter, Brea, CA) according to the Millipore PCR purification protocol. The purified PCR products were electrophoresed on an Agilent 2100 Bioanalyzer with a DNA 7500 kit and protocol (Agilent technologies, Inc., Santa Clara, CA) to determine the specificity and concentration of the amplified product.

BigDye Sequencing Reaction and Analysis {#s2e}
---------------------------------------

The purified PCR products were diluted to ∼1 ng/µL based on the concentrations determined by the Agilent Bioanalyzer and used as the templates for sequencing reactions. The PCR products were sequenced with a BigDye terminator V.3.1 cycle sequencing kit (Applied Biosystems). Three µL of diluted PCR product was sequenced in a 10 µL reaction containing 0.5 µL BigDye terminator V.3.1 ready reaction mix, 1.35 µL of 5× sequencing buffer, 2 µL of 1.6 µM sequencing primer and 3.15 µL H~2~O. The sequencing reactions were cleaned up with a Millipore Montage SEQ~384~ sequencing reaction cleanup kit (Millipore) on the Biomek FX workstation following Millipore\'s protocol (Beckman Coulter). Finally the sequencing reactions were analyzed with the ABI 3730*xl* DNA analyzer (Applied Biosystems). Subsequent sequence data was assembled and proofread using the DNASTAR Lasergene 8 software (DNASTAR, Madison, WI).

Phylogenetic Analysis {#s2f}
---------------------

The HPIV-1 genomes obtained from this study were analyzed using both the whole genome and also the individual genes. Among the 40 genome sequences obtained in the current study, five sequences (from isolates HPIV-1/WI/629-005/1997, HPIV-1/WI/629-D00057/2009, HPIV-1/WI/629-D02211/2009, HPIV-1/WI/629-D01774/2009, and HPIV-1/WI/629-D01250/2009) had gaps in coverage of some of the open reading frames (four had gaps in the HN gene). These sequences were excluded from phylogenetic analyses in which they did not have the complete genetic sequence (except in the case of the whole genome analysis). In addition, publicly available sequences from GenBank were also added to each analysis. Only those GenBank sequences obtained from wild-type HPIV-1 viruses that were greater than 100 bp in length were used for phylogenetic analyses.

Sequence alignments for the ORFs of individual genes were constructed using the Se-Al program (Rambaut et al., 1996). Because the collection year is known for most of the HPIV-1 sequences (for both the current strains and those from GenBank) and regression analysis using the program Path-O-Gen (Version 1.3) showed that there is clock-like evolution (data not shown), we used the Bayesian Markov Chain Monte Carlo (MCMC) method with a strict molecular clock in the BEAST program (Version 1.6.1) [@pone.0046048-Drummond1] to infer the time-scaled evolutionary relationships for HPIV-1. One of the 222 HN gene sequences in GenBank was missing collection date information so only 221 additional HN gene sequences were used for this analysis. The analysis incorporated the GTR model of nt substitution, with a different substitution rate estimated for each codon position. The chain length was set to 5 million. Trees were sampled every 1000 generations. The Maximum Clade Credibility (MCC) tree generated by BEAST was analyzed using TreeAnnotator (v 1.6.1, available at <http://beast.bio.ed.ac.uk>) with 10% burn-in. Statistical uncertainly is reflected in values of the 95% Highest Probability Density (HPD). The trees were viewed in FigTree (1.3.1, available at <http://beast.bio.ed.ac.uk>). Each clade is defined by long branches and nodes supported by high Bayesian posterior probability (BPP) values (\>0.9). Similar results were obtained using a relaxed clock model (SRD06 model, Bayesian Skyline prior, run 100 million generations) (Data not shown).

In addition to the analyses done with the BEAST program, the phylogenies for each gene were also inferred using the maximum likelihood method in PAUP [@pone.0046048-Swofford1] with high bootstrap (\>70%). For all of the genes other than the HN gene, only those sequences covering the entire coding region of the gene were used. For the HN gene, the phylogeny was inferred using nt positions 7245--8479 (nts 343--1577 of the 1728 nt HN gene) because this was the sequence range in which those HN gene sequences from our study and GenBank (used in the MCMC analysis) were primarily complete. The best-fit model of nucleotide substitution was tested and selected by MODELTEST [@pone.0046048-Posada1] as the general reversible model (GTR+I+G) with the frequency of each substitution, proportion of invariant sites (I) and the gamma distribution of among-site rate variation with four rate categories. The bootstrap resampling process (1,000 replications) was performed using the neighbor-joining (NJ) method to assess the robustness of each node on the tree.

Amino Acid Substitution among Clades {#s2g}
------------------------------------

The parsimony-based MacClade program [@pone.0046048-Maddison1] was used to determine amino acid changes in the proteins translated from the N, P, M, F, HN, and L genes.

Analysis of Nucleotide Diversity {#s2h}
--------------------------------

Analyses of nucleotide diversity were performed using DNAsp version 5.10.01 [@pone.0046048-Librado1]. The initial analysis was done using all of the genetic data obtained from this study plus the one HPIV-1 complete genome sequence that is currently available in GenBank (AF457102). This analysis showed that the HPIV-1 genome has a nucleotide diversity (*π* = the average number of nucleotide differences per site between two sequences) of 0.019 across the entire genome. However, 6,150 nts were excluded from this analysis because DNAsp does not include nt positions in which any sequence has missing data when performing nucleotide diversity analyses. After removing HPIV-1/629-005/1997, HPIV-1/629-D00057/2009, HPIV-1/629-D01250/2009, HPIV-1/629-D01774/2009 and HPIV-1/629-D02211/2010, which still have some sequence gaps, from the analysis, the nucleotide diversity was 0.018 and only excluded 273 positions. The similar nucleotide diversities indicates that the remaining 35 sequences are likely an accurate representation of what would be seen if all 40 sequences had complete genetic data. With this in mind we believe that using fewer, but more complete, sequences actually allowed us to perform a more accurate analysis of the genetic diversity of the HPIV-1 genome and performed all nucleotide diversity analyses with only the 35 complete genome sequences. Beside analysis of the complete genomes, nucleotide diversity was also determined for each non-coding region, gene, and intergenic region.

Genetic diversity was also calculated using a sliding scale analysis across the whole genome. The sliding scale analysis calculates the nucleotide diversity across a 100 bp window rather than across an entire section of the genome (e.g. an entire gene). The window was moved in 25 nt increments across the entire HPIV-1 genome and the nucleotide diversity was recalculated for each window. The population\'s mutation rate was estimated as Theta/site (from S) (the Watterson Estimator). Finally, the ratio of non-synonymous (Ka) to synonymous (Ks) mutations was also calculated in DNAsp using only the coding portions of the genome.

Recombination Analysis {#s2i}
----------------------

The 40 HPIV-1 genomes reported here and the genome sequence AF457102 retrieved from GenBank were analyzed for possible recombination using Recombination Detection Program v.3.31 [@pone.0046048-Gibbs1]--[@pone.0046048-Yang1] with three analysis methods: RDP, GENECONV, and BootScan.

Results {#s3}
=======

HPIV-1 Genome Sequencing Protocol {#s3a}
---------------------------------

We have developed an RT-PCR protocol capable of amplifying nucleotides (nts) 1--15575 of the 15600 nt genome of HPIV-1 in ten overlapping fragments. Following amplification it is possible to obtain an accurate sequence of the entire HPIV-1 genome minus approximately 30--100 nts at either end. Forty HPIV-1 strains including clinical specimens and low passage virus isolates were sequenced using the sequencing protocol developed in this study and complete genomes were obtained for 35 of 40 HPIV-1 strains ([Table 1](#pone-0046048-t001){ref-type="table"}). All 40 HPIV-1 sequences have been submitted to GenBank (accession numbers: JQ901971--JQ902010). The genome of HPIV-1 consists of the N-P(C/Y)-M-F-HN-L genes separated by intergenic sequences and flanked by a 5′ and 3′ non-coding region. The HPIV-1 intergenic sequence is CTT between the N-P, P-M, F-HN, and HN-L genes and is CGT between M-F genes. These three intergenic nts were highly conserved with no changes observed in sequences from either GenBank or this study. The terminators at the end of the HPIV-1 mRNAs are also highly conserved and similar among different genes. The sequence motif of the terminators is WADTAAGAAAAA. The third nt varies among A/T/G while the first position is consistently an A except in the L gene terminator where it is changed to a T. Also, a six nt addition was found from nt 4896--4901 of HPIV-1/WI/629-D01575/2009.

Phylogenetic analysis of HPIV-1 in Milwaukee, WI since 1997 {#s3b}
-----------------------------------------------------------

The Bayesian Markov Chain Monte Carlo (MCMC) analysis of 39 HPIV-1 genome sequences from viruses collected in Milwaukee, WI during 1997--2010 identified three major HPIV-1 clades, referred to as Clades 1, 2, and 3 ([Figure 1](#pone-0046048-g001){ref-type="fig"}). Clade 1 includes viruses from 1997--1999, Clade 2 includes viruses from 2005--2009, and Clade 3 includes the majority of 2009 viruses and all of the 2010 viruses. It is interesting to note that the HPIV-1 viruses in clade 2 are more closely related genetically to viruses from clade 1 (collected in 1997--1999), despite being closer temporally to the viruses from clade 3.The Bayesian MCMC analysis indicates that the Time to the Most Recent Common Ancestor (TMRCA) is 66.7--72.0 years (95% HPD). The rate of evolutionary change for these viral genomes is 7.61×10^−4^ nt substitutions per site per year (95% HPD, 6.93×10^−4^ to 8.29×10^−4^ nt/site-year), which is within the range typically observed for negative-sense RNA viruses [@pone.0046048-Jenkins1].

![The phylogenetic relationships of the 40 genomes and sequence AF457102 using the BEAST program.\
The phylogeny of 40 recently sequenced HPIV-1 genomes and one sequence from GenBank (AF457102) was estimated using a Bayesian Markov Chain Monte Carlo (MCMC) method with a strict molecular clock. Strain HPIV-1/c-35/1957 showed the greatest distance from the 39 1997--2010 Milwaukee viruses which is consistent with its isolation time. Colored rectangles (labeled clade 1--3) represent the three clades of the 39 1997--2010 Milwaukee viruses. The sequence from strain HPIV-1/WI/629-007/1997 is a singleton. The scale bar shows the unit for branch age. The numbers following the underscore in each name represent the collection date in number of years since collection date of the oldest HPIV-1 strain. To make the figure more legible identical sequences were removed from the table.](pone.0046048.g001){#pone-0046048-g001}

A second MCMC tree was made using 36 of the 40 newly identified HN gene sequences (four were excluded because they were incomplete) plus 221 HN gene sequences deposited in GenBank from previous studies [@pone.0046048-Newman1], [@pone.0046048-Henrickson3]--[@pone.0046048-Hetherington1], [@pone.0046048-Mizuta1] ([Figure 2](#pone-0046048-g002){ref-type="fig"}). The phylogeny was structured both by time and by location of isolation. Clades 1 and 3 identified during the whole genome phylogeny were also evident on the HN phylogeny. However, the viruses belonging to clade 2 (as defined by whole genome phylogeny in [Figure 1](#pone-0046048-g001){ref-type="fig"}) were interspersed with viruses from Japan on the HN gene tree. The TMRCA for the HN gene is estimated to be 58.3--66.2 (95% HPD), which is similar to the estimate for the complete genomes from Milwaukee 1997--2010. The rate of evolution for the HN gene is 1.37×10^−3^ nt substitutions per site per year (95% HPD: 1.16×10^−3^ nt/site-year to 1.59×10^−3^ nt/site-year, similar to the rest of the genome.

![The phylogenetic relationships of HN genes including 37 present sequences and 221 sequences from GenBank.\
The phylogeny of 258 HN gene sequences was analyzed using a Bayesian Markov Chain Monte Carlo (MCMC) method with a strict molecular clock in the BEAST program. Colored rectangles labeled clades 1--3 represent the three clades identified in [Figure 1](#pone-0046048-g001){ref-type="fig"} containing the 36 HPIV-1 sequences from the present study. Colored rectangles labeled genotypes C and D represent the HN gene sequences from HPIV-1 viruses collected in Milwaukee, WI in 1991. The number following the underscore in each name represents the collection date in years since collection date of the oldest HPIV-1 strain. Branch color corresponds to clade name/HN sequence seen in [Figure 3](#pone-0046048-g003){ref-type="fig"}.](pone.0046048.g002){#pone-0046048-g002}

In an effort to confirm the results of the BEAST analysis we also used the maximum likelihood method available in PAUP (version 4.0) [@pone.0046048-Swofford1]. The phylogenies created using the 40 newly identified HPIV-1 whole genomes and the N, P, M, F, HN and L gene sequences ([Figures S1](#pone.0046048.s001){ref-type="supplementary-material"}, [S2](#pone.0046048.s002){ref-type="supplementary-material"}, [S3](#pone.0046048.s003){ref-type="supplementary-material"}, [S4](#pone.0046048.s004){ref-type="supplementary-material"}, [S5](#pone.0046048.s005){ref-type="supplementary-material"}, [S6](#pone.0046048.s006){ref-type="supplementary-material"}, [S7](#pone.0046048.s007){ref-type="supplementary-material"}, [S8](#pone.0046048.s008){ref-type="supplementary-material"}) all look very similar to the MCMC tree created with complete HPIV-1 genomes in BEAST ([Figure 1](#pone-0046048-g001){ref-type="fig"}). The viruses are grouped in the same clade regardless of which gene is being analyzed. [Figures S1](#pone.0046048.s001){ref-type="supplementary-material"}, [S2](#pone.0046048.s002){ref-type="supplementary-material"}, [S3](#pone.0046048.s003){ref-type="supplementary-material"}, [S4](#pone.0046048.s004){ref-type="supplementary-material"}, [S5](#pone.0046048.s005){ref-type="supplementary-material"}, [S6](#pone.0046048.s006){ref-type="supplementary-material"}, [S7](#pone.0046048.s007){ref-type="supplementary-material"}, [S8](#pone.0046048.s008){ref-type="supplementary-material"}).

Amino Acid Substitutions {#s3c}
------------------------

Amino acid substitutions were identified using the 40 newly sequenced genomes and the MacClade program (Maddison and Maddison, 2000) for each HPIV-1 protein by translating the open reading frame (ORF) of each gene. Except for a few singleton mutations, most amino acid substitutions are clade-scale changes (substitutions occur in all strains within a clade). We observed substitutions in 1 of 525 (0.2%) amino acids of the N protein, 25 of 569 (4.4%) amino acids of the P protein, 0 of 349 (0.0%) amino acids of the M protein, 6 of 556 (1.1%) amino acids of the F protein, 36 of 576 (6.3%) amino acids of the HN protein, and 13 of 2224 (0.6%) amino acids of the L protein. The clade-scale amino acid substitutions are listed in [Table 3](#pone-0046048-t003){ref-type="table"} (complete genome sequences from this study) and shown graphically in [Figure 3](#pone-0046048-g003){ref-type="fig"} (HN gene sequences from this study and those found in GenBank).

![Amino acid sequence of the HN protein across all HPIV-1 clades.\
This figure shows the amino acid sequence of the HN protein across all HPIV-1 clades. Amino acid substitutions were determined with the MacClade program and the consensus HN gene sequence for each clade. The color of the branches in [Figure 2](#pone-0046048-g002){ref-type="fig"} correspond to the color of the clade name in this figure indicating which viruses have each of the sequences listed above.](pone.0046048.g003){#pone-0046048-g003}

10.1371/journal.pone.0046048.t003

###### Clade-Scale Amino Acid Substitutions from the N, P, M, F and L Proteins of 40 Recently Sequenced HPIV-1 Complete Genomes (the HN protein is described in greater detail in [Table 4](#pone-0046048-t004){ref-type="table"} and is not included here).

![](pone.0046048.t003){#pone-0046048-t003-3}

  Protein       Substitutions by clades               Multiple substitutions                                                                                                    
  ------------ ------------------------- ------------------------------------------------- ------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------
  **N gene**             None                                  None                                                               N498S                                                                                                   None
  **P gene**      N56S, P123S, P125L,     G110D, D185N, P231Q, S247P, K270R, T282A, V534A   N70D, I90V, I111V, P141S, S162F, P182S, T267I, S268G, S/P274L, S321G, S324P, V534A   F8S/L[a](#nt109){ref-type="table-fn"}, L151P/S[a](#nt109){ref-type="table-fn"}, G473S/T[a](#nt109){ref-type="table-fn"}
  **M gene**             None                                  None                                                                None                                                                                                   None
  **F gene**              E5K                                  N321S                                                       T493K, V526I, R546K                                                                            F8L/I[a](#nt109){ref-type="table-fn"}
  **L gene**         M718I, L1605F                     N199D, I210F, V2165I                              Q4L, V93I, T728A, I1176V, V1506I, N1598H, K1747R, T2209I                                                                         None

These residues have more than two amino acid variations.

When using the 40 new HN gene sequences in addition to those available in GenBank we found that 48 of 576 amino acids in the HN gene were variable (8.3%) ([Table 4](#pone-0046048-t004){ref-type="table"}). The HN protein is comprised of seven regions [@pone.0046048-Henrickson5]. Across these seven regions, the cytoplasmic tail (residues 1--35), the transmembrane region (residues 35--60), the stalk region (residues 60--191), the high structural homology region I (residues 191--341), the non-structural assignment region (residues 341--457), the high structural homology region II (residues 457--504) and the carboxyl terminus (residues 504--575) showed 4, 4, 9, 5, 12, 3, and 11 amino acid substitutions, respectively. The transmembrane and carboxy terminal regions showed the highest substitution rates (0.160 and 0.155 substitutions/residue, respectively), while the high structural homology regions I and II were the most conserved \[0.033 and 0.064 substitutions/residue, respectively ([Figure 3](#pone-0046048-g003){ref-type="fig"}, [Table 4](#pone-0046048-t004){ref-type="table"})\].

10.1371/journal.pone.0046048.t004

###### Amino Acid substitutions of the Seven Regions of HN Gene (calculated using all available sequences from GenBank).

![](pone.0046048.t004){#pone-0046048-t004-4}

  Region Name                               Location of region   Length of the region (Residues)   No. of Substitutions in each region   Ratio of substitution/residue
  ---------------------------------------- -------------------- --------------------------------- ------------------------------------- -------------------------------
  **Cytoplasmic tail**                            1--35                        35                                   4                                0.114
  **Transmembrane region**                        36--60                       25                                   4                                0.160
  **Stalk region**                               61--191                       131                                  9                                0.069
  **High structural homology region I**          192--341                      150                                  5                                0.033
  **Non-structural assignment region**           342--457                      116                                 12                                0.103
  **High structural homology region II**         458--504                      47                                   3                                0.064
  **Carboxyl terminal**                          505--575                      71                                  11                                0.155

Analysis of Sequence Variability {#s3d}
--------------------------------

The nucleotide diversity (*π*) is 0.018 across the entire genome (using the 35 complete genomes obtained in this study and the one complete genome previously available in GenBank). Nucleotide diversity was also calculated for important genetic elements of HPIV-1 including: 5′ and 3′ non-coding regions (NCRs), intergenic sequences, gene terminators, and open reading frames (ORFs). All of the non-coding regions were well conserved with the exception of the 5′ NCR of the F gene (π = 0.050) and 3′ NCR of the HN gene (π = 0.050), which were the most diverse regions of the genome. A 6 nt addition was found in the 5′ NCR of the F gene of HPIV-1/WI/629-D01575/2009. Among the six ORFs of the HPIV-1 genome, the P gene is the most variable (π = 0.023) and the L gene is the most conserved (π = 0.014) ([Table 5](#pone-0046048-t005){ref-type="table"}).

10.1371/journal.pone.0046048.t005

###### Genetic Diversity Across the HPIV-1 Genome.
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  Region                                       Positions               Sites analyzed               Polymorphic (Segregating) Sites    Average nucleotide differences (*k*)         Nucleotide Diversity (*π*)         Theta/Site from S
  ------------------------------------------ -------------- ------------------------------------- ----------------------------------- --------------------------------------- --------------------------------------- -------------------
  5′ Leader                                      1--55       N/A[a](#nt110){ref-type="table-fn"}                   0                                   0.000                                   0.000                         0.000
  N 5′ NCR[b](#nt111){ref-type="table-fn"}      56--116      17[b](#nt111){ref-type="table-fn"}    7[b](#nt111){ref-type="table-fn"}   1.319[b](#nt111){ref-type="table-fn"}   0.078[b](#nt111){ref-type="table-fn"}         0.099
  N Gene                                       120--1694                    1575                                  157                                 23.444                                   0.015                         0.024
  N 3′ NCR                                     1695--1737                    43                                    7                                   1.438                                   0.033                         0.039
  N/P -- IG Spacer                             1738--1740                     3                                    0                                   0.000                                   0.000                         0.000
  P 5′ NCR                                     1741--1843                    103                                  13                                   2.073                                   0.020                         0.030
  P Gene                                       1844--3550                   1706                                  233                                 39.595                                   0.023                         0.033
  P 3′ NCR                                     3551--3633                    83                                   14                                   2.454                                   0.030                         0.041
  P/M -- IG Spacer                             3634--3636                     3                                    0                                   0.000                                   0.000                         0.000
  M 5′ NCR                                     3637--3668                    32                                    5                                   0.383                                   0.012                         0.038
  M Gene                                       3669--4715                   1046                                  113                                 17.873                                   0.017                         0.026
  M 3′ NCR                                     4716--4809                    94                                   16                                   2.506                                   0.027                         0.041
  M/F -- IG Spacer                             4810--4812                     3                                    0                                   0.000                                   0.000                         0.000
  F 5′ NCR                                     4813--5087                    269                                  80                                  13.433                                   0.050                         0.072
  F Gene                                       5088--6755                   1667                                  179                                 29.105                                   0.017                         0.026
  F 3′ NCR                                     6756--6843                    88                                   17                                   2.433                                   0.028                         0.047
  F/HN -- IG Spacer                            6844--6846                     3                                    0                                   0.000                                   0.000                         0.000
  HN 5′ NCR                                    6847--6902                    56                                   14                                   1.663                                   0.030                         0.060
  HN Gene                                      6903--8630                   1728                                  209                                 35.375                                   0.020                         0.029
  HN 3′ NCR                                    8631--8740                    109                                  23                                   5.429                                   0.050                         0.051
  HN/L -- IG Spacer                            8741--8743                     3                                    0                                   0.000                                   0.000                         0.000
  L 5′ NCR                                     8744--8771                    28                                    1                                   0.056                                   0.002                         0.009
  L Gene                                      8772--15443                   6668                                  588                                 96.384                                   0.014                         0.021
  L 3′ NCR                                    15444--15543    3[b](#nt111){ref-type="table-fn"}                    1                                   0.356                   0.119[b](#nt111){ref-type="table-fn"}         0.080
  Tail Sequence                               15544--15606   N/A[a](#nt110){ref-type="table-fn"}                                                                                                                      
  WHOLE GENOME                                  1--15606                    15333                                1677                                 275.319                                  0.018                         0.026

Sites could not be analyzed due to missing sequence data.

Partial sequence of this region was not analyzed due to missing sequence data. The calculated nucleotide difference and diversity is not the accurate representation of the 5′ NCR.

The complete results of the sliding scale analysis of nucleotide diversity can be seen in [Figure 4](#pone-0046048-g004){ref-type="fig"}. The 100 bp regions containing the 5′ NCR plus the first 5 nt of the F gene (nt 4983--5082) and the 3′ NCR of the HN gene (nt 8609--8709) showed the greatest nucleotide diversity (π = 0.066, π = 0.058) across the entire genome. The most diverse region of each open reading frame is from nts 650--749 (π = 0.032) for the N gene, 2600--2699 (π = 0.045) for the P gene, 4452--4551 (π = 0.027) for the M gene, 5083--5182 (π = 0.042) for the F gene, 7884--7983 (π = 0.042) for the HN gene, and 13939--14038 (π = 0.043) for the L gene ([Figure 4](#pone-0046048-g004){ref-type="fig"}).

![Sliding Scale Analysis of Nucleotide Diversity of the HPIV-1 Genome.\
Analysis of nucleotide diversity was done in 100 nt windows in 25 nt increments. A table showing each window and its diversity can be seen in supplementary document 1. A schematic of the HPIV-1 genome can be found at the bottom of the figure. The coding region of each gene is labeled.](pone.0046048.g004){#pone-0046048-g004}

Analyses of Selective Pressure {#s3e}
------------------------------

The Ka/Ks ratio for the coding region of each gene ranges from 0.034--0.233 (values less than one are indicative of purifying/negative selection). The P gene has the greatest Ka/Ks ratio of all HPIV-1 genes (0.233) and the M gene has the smallest Ka/Ks ration (0.034).

Recombination Analysis {#s3f}
----------------------

Finally, we used the Recombination Detection Program (RDP) to identify possible recombination events among the 40 whole-genome HPIV-1 sequences. This analysis indicated that none of the strains that we sequenced exhibited any signs of recombination, which is consistent with the phylogenetic analyses performed in this study ([Figures S1](#pone.0046048.s001){ref-type="supplementary-material"}, [S2](#pone.0046048.s002){ref-type="supplementary-material"}, [S3](#pone.0046048.s003){ref-type="supplementary-material"}, [S4](#pone.0046048.s004){ref-type="supplementary-material"}, [S5](#pone.0046048.s005){ref-type="supplementary-material"}, [S6](#pone.0046048.s006){ref-type="supplementary-material"}, [S7](#pone.0046048.s007){ref-type="supplementary-material"}, [S8](#pone.0046048.s008){ref-type="supplementary-material"}).

Discussion {#s4}
==========

By developing a novel PCR-based complete genome sequencing protocol for HPIV-1, we were able to provide the first evolutionary analysis of HPIV-1 at the complete whole genome level. Thirty-nine HPIV-1 genome sequences were obtained directly from clinical nasal swab specimens and/or viral isolates from 1997--1999, 2005, 2007 and 2009--2010 collected in Milwaukee, WI (and an additional sequence was obtained from an HPIV-1 isolate from ATCC). These data were combined with HPIV-1 gene sequences publicly available in GenBank.

Previous evolutionary studies of HPIV-1, based on the HN gene sequence, indicate that evolution is guided by a combination of co-circulating strains and the development of geographically restricted lineages [@pone.0046048-Henrickson3]--[@pone.0046048-Hetherington1]. The sequences used for the present analysis include those used in previous analyses and a significant number of additional sequences, which increases the overall temporal and geographic distribution of HPIV-1 sequence data. Previous studies of HPIV-1 in Milwaukee, WI revealed that two distinct HPIV-1 genotypes were circulating in Milwaukee during 1991 (genotypes C and D), confirmed by this study ([Figure 2](#pone-0046048-g002){ref-type="fig"} and [Figure S7](#pone.0046048.s007){ref-type="supplementary-material"}) [@pone.0046048-Henrickson3]. The current study indicates that two distinct HPIV-1 viruses continue to circulate in Milwaukee, WI; however, both are derived from genotype C. Even though no HPIV-1 genotype D viruses were detected, it remains possible that HPIV-1 genotype D may still be present in different parts of the country or even in WI, but if it has stopped circulating it would be interesting to look at nt polymorphisms or amino acid substitutions specific to this genotype to see if they may have contributed to its extinction (e.g. HN amino acid substitutions T7I and M445I).

We inferred the phylogenies of the HPIV-1 complete genome and the HPIV-1 HN gene using Bayesian Markov Chain Monte Carlo analysis (MCMC) with current sequences and those available in GenBank. The analyses showed that the topology of the whole genome tree was similar to that seen for the HN gene and supported the same three clade topology for the 1997--2010 Milwaukee viruses. While the TMRCA estimated for the HN gene and the whole genome were similar \[58.3--66.2 years (95% HPD) and 66.7--72.0 years (95% HPD), respectively\], the substitution rates obtained with these two analyses differed slightly (1.37×10^−3^ nt substitutions per site per year and 7.61×10^−4^ nt substitutions per site per year, respectively). With everything being equal this result indicates that the HN gene evolves more rapidly than the rest of the genome. However, the HN gene analysis contained nearly six times the number of sequences from a greater temporal and geographic distribution, and the difference in substitution rates is more indicative of sequence availability rather than a true difference in evolutionary rate. With that being the case, these results suggest that the HN gene evolves in a manner similar to that of the whole genome and that the HN gene may be an appropriate model for HPIV-1 evolution when whole genome sequences are not available. In order to get a better idea whether this finding is appropriate we would need to look at additional HPIV-1 whole genomes from different geographic locations.

In addition to a broad overview of the evolutionary pattern seen in HPIV-1 we also performed more in depth analyses on the HPIV-1 genome sequences by looking at nucleotide diversity and selection pressure. As was mentioned previously, an analysis of nucleotide diversity revealed that the 5′ NCR of the F gene and the 3′ NCR of the HN gene were the most diverse non-coding regions of the genome. Previous reports indicate that the 5′ NCR of the F gene contains cis-acting elements that affect transcriptional termination [@pone.0046048-Bousse2] and may regulate the level of read through transcription across the M-F junction and subsequent F protein production [@pone.0046048-Rassa1]. We also looked at the diversity in the coding regions of the HPIV-1 genome using both analyses of nt substitution \[nucleotide diversity (π)\] and amino acid substitution \[(non-synonymous/synonymous substitution rate (Ka/Ks)\]. The non-synonymous/synonymous (Ka/Ks) mutation ratios of less than 1 that is seen in all HPIV-1 genes indicates that, as a whole, HPIV-1 proteins are under purifying/negative selection. However, some proteins seem much more tolerant of amino acid substitutions than others. For example, it is interesting to note that the Ka/Ks ratios for the HN and P genes are approximately 3--8 times greater than the ratios for all other HPIV-1 genes ([Table 6](#pone-0046048-t006){ref-type="table"}), which may indicate that these genes are more tolerant of non-synonymous mutations.

10.1371/journal.pone.0046048.t006

###### Nonsynonymous (Ka) vs. Synonymous Mutations in the Coding Region of HPIV-1 Genes.
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  Region        Positions    Average Ka   Average Ks   Ka/Ks
  ----------- ------------- ------------ ------------ -------
  N Gene        120--1694      0.002        0.060      0.040
  P Gene       1844--3550      0.014        0.061      0.233
  M Gene       3669--4715      0.002        0.067      0.034
  F Gene       5088--6755      0.004        0.062      0.071
  HN Gene      6903--8630      0.011        0.057      0.185
  L Gene       8772--15443     0.002        0.060      0.041
  ALL GENES     1--15606       0.005        0.060      0.083

At first blush it seems counterintuitive that a protein, such as the HN, with so many important functions would be among the most tolerant of amino acid substitution. One previous study reports that residues 184, 262, 264, 277, 279, 420, 461, and 541 play a role in hemaglutinase and neuraminidase function, while another indicates that residue 55 plays a key role in envelope fusion, and yet another describes how the conserved cysteine and proline residues around residue 461 are important to the viral structure [@pone.0046048-Lyn1], [@pone.0046048-Thompson1], [@pone.0046048-Bousse3]. However, as a surface protein, and one of the primary immunogens of HPIV-1, an increased tolerance of non-synonymous mutations outside of these key functional domains would likely aid the virus\' ability to escape the host immune response. In support of this hypothesis, the current study shows that the residues previously identified as having a functional role showed little to no variation over the last 30 years while the remainder of the protein is more tolerant of amino acid substitution.

The P gene region encodes the P, C, C\', Y1 and Y2 proteins. These viral accessory proteins aid the L protein in transcription/translation of viral nucleic acid and also aid in suppression of the host innate immune response by acting as antagonists to the IFN and apoptosis pathways [@pone.0046048-Chambers1]. The rationale for an increased Ka/Ks ratio in the P protein might be linked to the function of these accessory proteins that would benefit from increased diversity.

While the F gene showed less overall diversity than either the HN or P gene (in terms of nucleotide diversity and Ka/Ks ratio), portions of the gene are among the most conserved and the most diverse in the whole genome. Nts 5383--6107 are among the least tolerant of mutation, which is somewhat expected as this region contains the previously identified F protein cleavage site (the QTRFFG motif seen at F protein residues 110--115 was completely conserved among all 40 HPIV-1 sequences from this study) [@pone.0046048-Ambrose1]. Meanwhile, nts 6233--6382 are among the most tolerant of mutation. As with the HN protein, the F protein is an important virus surface protein and increased variation in certain regions of the F protein may help the virus avoid the immune system.

Despite the N gene/protein being among the most conserved in HPIV-1, we did find a hypervariable region at the C-terminus of the N protein. Studies of Sendai virus found that this region is required for proper template function during RNA synthesis [@pone.0046048-Curran1]. The N protein of Sendai virus and HPIV-1 share common structures and functional sites and as such the variable regions found in the N protein of HPIV-1 might have a similar function in RNA synthesis. The substitutions found at residues 442 have been documented previously in a mutant virus [@pone.0046048-Dave1]--[@pone.0046048-Matsuoka1]. In this study, we show that these substitutions are common in all three clades of 1997--2010 Milwaukee HPIV-1 viruses and that they have remained consistent for over a decade.

Finally, we performed an analysis to see if any of these viruses have undergone recombination. Natural recombination events have been detected in several other members of the *Paramyxoviridae* family including Newcastle disease virus (NDV) [@pone.0046048-Han1]--[@pone.0046048-Zhang1] and human respiratory syncytial virus [@pone.0046048-Spann1]. Attenuated vaccines are capable of influencing the evolution process of NDV through exchanging their genetic material with circulating viruses [@pone.0046048-Chong1]. Recently, Yang et al [@pone.0046048-Yang1] identified a naturally occurring HPIV-3 recombinant virus. In our recombination analysis of the 40 genomes reported in this study, we found no indication that any recombination events occurred. This result seems logical considering the fact that the topology of phylogenetic trees for each HPIV-1 gene group together in a nearly identical manner.

This work represents a significant step forward in filling the void of much needed HPIV-1 genetic data. Our hope is that the genome sequencing protocol we provide here will facilitate an even greater increase in HPIV-1 genetic data from diverse locales and time periods. This increase in genetic data may in turn lead to breakthroughs in the development of novel HPIV-1 therapeutics, vaccines and diagnostic assays. In the meantime, the genetic data provided by this study should lead to an increased understanding of HPIV-1 evolution, gene structure and function, viral pathogenesis, and conserved domains that can function as targets for molecular diagnostic assays.

Supporting Information {#s5}
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**Phylogenetic relationship of HPIV-1 whole genomes with the maximum likelihood method in PAUP.** The accession number of the sequence from GenBank is AF457102.

(TIF)
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Click here for additional data file.

###### 

**Phylogenetic relationship of HPIV-1 N gene including five sequences from GenBank with the maximum likelihood method in PAUP.** The accession nos. of the five GenBank sequences are: D01070, EU346886, M62850, S38060 and AF457102.

(TIFF)
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Click here for additional data file.

###### 

**Phylogenetic relationship of HPIV-1 P gene including five sequences from GenBank with the maximum likelihood method in PAUP.** The accession nos. of the five GenBank sequences are: M37792, M74080, M74081, M74082, and AF457102.

(TIFF)
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Click here for additional data file.

###### 

**Phylogenetic relationship of HPIV-1 M gene including three sequences from GenBank with the maximum likelihood method in PAUP.** The accession nos. of the three GenBank sequences are: M80818, S38067 and AF457102.

(TIFF)
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Click here for additional data file.

###### 

**Phylogenetic relationship of HPIV-1 F gene including three sequences from GenBank with the maximum likelihood method in PAUP.** The accession nos. of the three GenBank sequences are: AF016279, AF457102 and M22347.
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Click here for additional data file.
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**Phylogenetic relationship of HPIV-1 HN gene using sequences from the current study only with the maximum likelihood method in PAUP.**
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Click here for additional data file.
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**Phylogenetic relationship of HPIV-1 HN gene including 221 sequences from GenBank with the maximum likelihood method in PAUP.**
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Click here for additional data file.
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**Phylogenetic relationship of HPIV-1 L gene including two sequences from GenBank with the maximum likelihood method in PAUP.** The accession nos. of the two GenBank sequences are: AF117818 and AF457102.
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Click here for additional data file.
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